星洲熱股評析
CEO转任董事经理．马化学药业战略不变
2017-12-06 09:13
马化学药业首席执行员李奥纳阿里夫将转任董事经理一职，让业务分拆后管理团队豁然开朗，达证券相信这将确保集团在2022年崛起为东盟前5大仿制药集团战略路线不变，对未来发展是一大利多。
（吉隆坡5日讯）马化学药业（CCMDBIO，7148，主板消费品组）首席执行员李奥纳阿里夫将转任董事经理一职，让业务分拆后管理团队豁然开朗，达证券相信这将确保集团在2022年崛起为东盟前5大仿制药集团战略路线不变，对未来发展是一大利多。
达证券说，李奥纳阿里夫自2008年掌权以来，已积极通过和韩国P a n G e n生物科技有限公司和印度Biocon有限公司等全球制药公司结盟，并崛起成为国内最大红血球生成素（Erythropoietin）和胰岛素（Insulin）制造商。
马化学药业是在2015年宣布，放眼生产更多仿制药产品来提高营业额和捍卫赚益，以稀释本地和东南亚市场竞争激烈的学名药市场影响。
达证券说，除了盈利增长潜能和可观的周息率外，马化学药业进军高价利基的治疗产品前景看俏，因此维持其“买进”评级，目标价为2令吉70仙。
文章来源：
星洲日报‧财经‧2017.12.06
http://www.sinchew.com.my/node/1707908/ceo转任董事经理．马化学药业战略不变
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
More articles on 星洲熱股評析
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2024-07-18 16:05:00
EMA 5
5 Mins
SELL
2024-07-18 16:00:00
OBV
30 Mins
SELL
2024-07-18 16:00:00
OBV
10 Mins
SELL
2024-07-18 16:00:00
EMA 5
5 Mins
BUY
2024-07-18 15:45:00
OBV
5 Mins
BUY
Apps
Top Articles
1
CEO Morning Brief
PGF Capital to Distribute Thermal Insulated Panels for Data Centres
3
Good Articles to Share
4
Rakuten Trade Research Reports
5
6
Bimb Research Highlights
7
The Alpha Trader
8
Chloe Tai Blog
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
